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ABSTRACT:
The transcription factor MycN is the prototypical neuroblastoma oncogene and 
a potential therapeutic target. However, its strong expression caused by gene 
amplification in about 30% of neuroblastoma patients is a considerable obstacle to 
the development of therapeutic approaches aiming at eliminating its tumourigenic 
activity.  We  have  previously  reported  that  B-Myb  is  essentially  required  for 
transcription of the MYCN amplicon and have also shown that B-MYB and MYCN are 
engaged in a feed forward loop promoting the survival/proliferation of neuroblastoma 
cells. We postulated that pharmacological strategies breaking the B-MYB/MYCN axis 
should result in clinically desirable effects. Thus, we implemented a high throughput 
chemical screen, using a curated library of ~1500 compounds from the National 
Cancer Institute, whose endpoint was the identification of small molecules that 
inhibited B-Myb. At the end of the screening, we found that the compounds pinafide, 
ellipticine and camptothecin inhibited B-Myb transcriptional activity in luciferase 
assays. One of the compounds, the topoisomerase-1 inhibitor camptothecin, is of 
considerable clinical interest since its derivatives topotecan and irinotecan are 
currently used as first and second line treatment agents for various types of cancer, 
including neuroblastoma. We found that neuroblastoma cells with amplification of 
MYCN are more sensitive than MYCN negative cells to camptothecin and topotecan 
killing. Campothecin and topotecan caused selective down-regulation of B-Myb and 
MycN expression in neuroblastoma cells. Notably, forced overexpression of B-Myb 
could antagonize the killing effect of topotecan and camptothecin, demonstrating 
that the transcription factor is a key target of the drugs. These results suggest 
that camptothecin and its analogues should be more effective in patients whose 
tumours  feature  amplification  of  MYCN  and/or  overexpression  of  B-MYB.
INTRODUCTION
Neuroblastoma is a tumour of the sympathetic 
nervous system and the most common extracranial 
solid tumour in childhood. It represents more than 7% 
of malignancies in patients younger than 15 years and 
around 15% of all paediatric oncology deaths. The overall 
incidence is about one case in 7,000 live births, and there 
are about 700 new cases per year in the United States [1, 
2].
Amplification of MYCN is the most common genetic 
aberration associated with poor outcome in neuroblastoma 
[3, 4], occurs in roughly 30% of primary tumours and is 
strongly correlated with advanced disease and treatment 
failure [5, 6]. Its association with poor outcome in 
patients with otherwise favourable disease features, Oncotarget 2012; 3:  535-545 536 www.impactjournals.com/oncotarget
such as localized tumours or INSS stage 4S disease, 
underscores its biological importance [7-9]. The MYCN 
proto-oncogene encodes a 60-63 KDa protein (MycN) 
that is exclusively expressed in the developing nervous 
system, unlike its paralogue c-MYC, which is expressed 
ubiquitously [10]. Like all Myc family proteins, MycN 
contains an N-terminal transactivating domain (MYC box) 
and a C-terminal region containing a basic-helix-loop-
helix/leucine zipper (bHLH-LZ) motif, which mediates 
DNA binding as well as binding to other bHLH-LZ 
proteins such as Max and Mad [11].
MYCN is located on the distal short arm of 
chromosome 2 (2p24): a large region from this site 
becomes amplified and the MYCN locus is copied to form 
an extrachromosomal circular element, or DM (double-
minute chromatin bodies), with retention of the normal 
copies of MYCN at 2p24. DMs might accumulate by 
uneven segregation during mitosis; however, in some 
cases, the amplified DNA integrates into a chromosomal 
locus to form an HSR (homogeneously staining regions) 
[12-15]. Other genes might be co-amplified with MYCN 
in a subset of cases, but MYCN is the only gene that is 
consistently amplified from this locus [4].
The vertebrate Mybs comprise a small family of 
transcription factors. The prototypical member, c-Myb, 
is the cellular homologue of the oncogene carried by 
the AMV and E26 chicken retroviruses that transform 
haematopoietic cells in vivo and in vitro [16]. The two 
other members of the family, A-Myb and B-Myb, share 
a similar protein domain organization and bind to the 
same consensus sequence on the DNA [17-19]. B-MYB 
is expressed early during mouse embryogenesis, and 
is associated with cell proliferation. Consistent with 
this, B-MYB knock-out mice die at a very early stage 
of development, and the requirement for B-Myb in 
inner cell mass formation is indicated by the severely 
impaired proliferation of these pluripotent cells when 
blastocysts were explanted and cultured in vitro [20-24]. 
B-MYB antisense oligonucleotides inhibit proliferation 
of normal and transformed cell lines, while constitutive 
B-MYB  expression  allows  BALB/c  3T3  fibroblasts  to 
grow in low serum conditions and prevents cell cycle 
arrest and differentiation of M1 myeloid leukaemia 
cells treated with interleukin (IL)-6 [25-27]. B-Myb is 
a relatively weak, ubiquitous transcription factor and in 
normal physiological settings it is not essential for the 
transcription of MYCN, whose expression is strictly tissue 
specific. However, in neuroblastoma the generation of 
multiple copies of the MYCN gene causes accumulation 
of the MycN oncoprotein, which binds to the B-MYB locus 
and activates its unregulated expression. This will initiate 
a pathological regulatory cycle where B-Myb, in spite of 
its intrinsically weak transcriptional activity, will cause a 
significant enhancement of MYCN expression due to the 
large number of template amplicons available [28]. Given 
their reliance on B-MYB, neuroblastoma tumours with 
amplification of MYCN should be exquisitely sensitive 
to its pharmacological targeting, suggesting that small 
Figure 1: Chemical screen. Each dot represents relative luciferase activity (RLU) expressed as percentages relative to the value 
obtained in cells treated with the vehicle DMSO (indicated by the black diamond and ctrl), which was set as 100%. The highlighted 
compound codes 50N E8, 50N G9, and 63 F6 indicate ellipticine, camptothecin and pinafide, respectively. Oncotarget 2012; 3:  535-545 537 www.impactjournals.com/oncotarget
molecule inhibitors of B-Myb could have important 
clinical applications. 
RESULTS AND DISCUSSION
A  chemical  screen  identifies  small-molecule 
transcriptional inhibitors of B-Myb.
To identify small molecules with the potential 
of inhibiting B-Myb transcriptional activity and, 
consequently, its downstream genes such as MYCN, 
we used 2 chemical libraries from the National Cancer 
Institute (NCI), i.e. the diversity set II and the natural 
product set. Each chemical compound was assessed 
in a high throughput assay with a neuroblastoma cell 
line stably transfected with a MYB responsive promoter 
linked to the luciferase gene and a B-MYB expression 
vector. The aim was to find compounds that inhibited 
B-Myb transcriptional activity more than 50% compared 
to control. At the end of the screening, we observed that 
several compounds showed various degrees of inhibitory 
activity. Curiously, some compounds were activators of 
B-Myb transcriptional activity, but were not investigated 
further (Fig. 1). The compounds ellipticine, pinafide and 
camptothecin were selected for further analysis given 
their  potential  anticancer  activity,  and  we  confirmed 
Figure 2: Validation of compounds identified in the primary screen. GIMEN (MYCN non-amplified neuroblastoma cells) 
were transiently co-transfected with the MYB-responsive promoter pGL2-mim1 and the pcDna-B-MYB/empty vectors or with the p53 
responsive p21luc promoter and pCMVp53/empty vectors. A renilla luciferase plasmid was added to the transfection mix for normalisation. 
Cells were treated with the compounds ellipticine, pinafide and camptothecin at the indicated concentrations for 24h. Error bars indicate 
standard deviations and the asterisk indicates statistically significant differences (Student’s T test p ≤ 0,05) between the activities of cells 
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their ability to suppress B-Myb transcriptional activity 
in independent transient transfection luciferase assays 
(Fig. 2A). As a control, we verified that the inhibitory 
effect on p53-mediated transactivation was weak, 
corroborating the hypothesis that the effect of the 
compounds is, at least to some extent, specific to B-Myb 
(Fig. 2B). Pinafide, ellipticine and camptothecin, are plant 
antibiotics with a vague structural similarity, all containing 
aromatic rings with nitrogen atoms. Camptothecin and 
ellipticine are known topoisomerase 1 and 2 inhibitors, 
respectively. They cause DNA damage and are used as 
chemotherapeutic drugs [29-32]. Two water-soluble 
derivatives of camptothecin, topotecan and irinotecan, 
are in use as first or second line antineoplastic agents in a 
variety of cancers, including neuroblastoma [32-37].
Biological  effects  of  the  B-Myb-inhibiting 
compounds in neuroblastoma cell lines.
We used camptothecin, pinafide and ellipticine in 
proliferation assays with a panel of MYCN amplified or 
non-amplified cell lines. Pinafide showed some killing 
activity at the highest concentrations used, i.e. 250-
500 nM, independently from the presence of MYCN 
amplification  (Fig.  3A,B).  Neuroblastoma  cell  lines 
were resistant to escalating doses of ellipticine up to 
a concentration of 500nM, with the exception of SH-
SY5Y cells which were inhibited by high concentrations 
of the drug (Fig. 3B). Notably, neuroblastoma cell lines 
with amplification of MYCN were extremely sensitive 
to concentrations of camptothecin or its clinical analog 
topotecan as low as 10-20 nM (Fig. 4A), whereas non-
amplified cell lines proliferated normally at these drug 
concentrations (Fig. 4B). To investigate in more detail the 
effect on proliferation and cell survival of camptothecin 
and topotecan in neuroblastoma cells, we carried out 
propidium iodide DNA staining and FACS analysis. In 
agreement with the MTT assay, in the presence of the 
drugs we observed a marked increase of cells blocked 
in the S or G2 phase of the cell cycle and an increase 
of fragmented, hypodiploid DNA, but only in cells 
with  MYCN  amplification.  In  contrast,  non-amplified 
neuroblastoma cells showed a normal cell cycle profile 
in the presence of 10-20 nM camptothecin or topotecan 
(Fig. S1).  Camptothecin and its analogues inhibit 
topoisomerase 1, therefore the observed effects could be 
explained if topoisomerase 1 expression were higher in 
MYCN-amplified, compared with MYCN non-amplified 
cell lines. However, the expression of topoisomerase-1 
is highly variable among the different neuroblastoma cell 
lines and unrelated to the amplification status of MYCN, 
suggesting that the killing effect is independent from 
topoisomerase-1 expression (Fig. S2). 
The  B-MYB-MYCN  axis  is  disrupted  by 
camptothecin and its clinical analogue topotecan.
B-MYB and MYCN are engaged in a feed forward 
loop sustaining the expression of each other. Furthermore, 
B-Myb autoregulates its own expression.[38] Thus, we 
hypothesised that, by inhibiting B-Myb transcriptional 
activity, camptothecin and topotecan could also disrupt 
the expression of B-MYB and of its target gene, MYCN. 
Indeed, we observed that expression of B-Myb and MycN 
Figure 3: MTS proliferation assay in neuroblastoma cell lines exposed to ellipticine and pinafide. Proliferation of MYCN 
amplified (panel A) or MYCN non amplified (panel B) cells in the presence of increasing concentrations of Ellipticine and Pinafide, as 
indicated. Note that cell viability is only reduced by high concentrations (250-500nM) of pinafide, in a MYCN-independent manner. 
Neuroblastoma cell lines were generally resistant to the killing effect of ellipticine. Error bars indicate standard deviations. Oncotarget 2012; 3:  535-545 539 www.impactjournals.com/oncotarget
is downregulated by the drugs in 3 out of 4 MYCN-
amplified cell lines (Fig. 5). The effect is not a mere 
consequence of reduced proliferation or cell death, since 
expression of cell cycle genes, such as cyclin A and cyclin 
B, or the housekeeping gene GAPDH is unaffected (Fig. 
6). The increased expression of cyclin A/B by the drugs 
probably reflects the high number of cells blocked at the S 
and G2/M phases of the cell cycle (Fig. S1). We observed 
PARP fragmentation in drug-responsive cells, diagnostic 
of apoptosis (Fig. 6). Interestingly, camptothecin and 
topotecan did not cause inhibition of B-Myb/MycN 
expression and PARP cleavage in SK-N-BE2 cells. SK-N-
BE2 cells contain mutated p53 [39] and it was previously 
observed that B-MYB expression is activated in cell 
lines with mutation of p53, perhaps explaining the drug-
resistant phenotype [40]. 
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Forced expression of B-MYB confers resistance to 
camptothecin and topotecan in a MYCN amplified 
cell line.
To demonstrate that the killing effect of camptothecin 
and topotecan in MYCN-amplified cell lines is caused by 
inhibition of B-Myb, we carried out a rescue experiment. 
To this end, we transfected LAN-5 cells with empty or 
B-MYB expression vectors. We then selected two clones 
expressing high levels of B-Myb (Fig. S3) and exposed 
them to 10-20nM topotecan or camptothecin. Notably, the 
inhibition of cell proliferation caused by the drugs was 
partially rescued by ectopic expression of B-MYB (Fig. 7). 
This experiment demonstrates that B-Myb is a key target 
of the drugs in neuroblastoma cells with amplification of 
MYCN. 
Recent studies have revealed that B-Myb might 
promote cell cycle progression and cell survival by co-
ordinating the expression of G2/M genes also by recruiting 
other transcription factors, such as FoxM1 [41]. B-MYB 
is overexpressed and amplified in a number of cancers, 
including breast, ovary, leukaemia and neuroblastoma 
and we have shown that neuroblastoma cells are addicted 
to B-MYB expression, but only in the context of MYCN 
amplification.  B-Myb  physically  binds  to  the  MYCN 
amplicon and is required for MycN expression. On the 
other hand, MycN promotes B-Myb transcription, feeding 
a positive loop that promotes survival of neuroblastoma 
cells [28]. Our new study shows that camptothecin 
and its clinically used derivative topotecan inhibit the 
transcriptional activity of B-Myb, inducing synthetic 
Figure 4: MTS proliferation assay in neuroblastoma cell lines exposed to camptothecin (CPT) or topotecan (TPT). 
A) MYCN-amplified NB cells; B) MYCN non-amplified NB cells. Error bars indicate standard deviations and statistical significance was 
verified by Student’s T test (*= p<0,05 **=p<0,01 ***=p<0,001 of 48hrs 10v20v250nM vs. CTR; 72h 10v20v250nM vs. CTR )
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Figure 6: Effects of camptothecin (CPT) and topotecan (TPT) on cell cycle proteins and PARP cleavage. Western blot 
analysis showing the expression of Cyclin A and cyclin B in the indicated neuroblastoma cell lines treated with CPT or TPT (20nM) for 
8-16-24-32hrs. Cleavage of PARP is indicated by the appearance of a 89KDa fragment. The housekeeping gene GAPDH was used as 
loading control. 
Figure 5: Effects of camptothecin (CPT) and topotecan (TPT) on the B-MYB/MYCN axis. Western blot analysis showing the 
expression of B-Myb and MycN in the indicated neuroblastoma cell lines treated with CPT or TPT (20nM) for 8-16-24-32hrs. Expression 
of the housekeeping gene GAPDH was used as loading control.
Figure 7: B-MYB rescues the killing effect of camptothecin (CPT) and topotecan (TPT) in MYCN amplified cells. 
MTS proliferation assay showing the effect of CPT and TPT in LAN-5 cell clones transfected with pCMV-empty or pCMV-B-MYB 
plasmids. Bars indicate densitometric values relative to vehicle treated controls. Standard deviations is indicated by the error bars, statistical 
significance was assessed using the Student’s T-test (*= p<0,05; **=p<0,01; ***=p<0,001; o= p<0,05 oo=p<0,01; ooo=p<0,001;)Oncotarget 2012; 3:  535-545 542 www.impactjournals.com/oncotarget
lethality in MYCN positive cells at dosages below 
the plasma concentrations attained in cancer patients 
undergoing treatment [42-44]. Thus, the molecular make 
up of neuroblastoma tumours is highly relevant to the 
sensitivity to camptothecin analogues. It will be interesting 
to verify whether the clinical response to these drugs is 
associated with the amplification status of MYCN and/or 
overexpression of B-MYB in neuroblastoma patients. If 
clinical studies will confirm this association, it is possible 
to envisage that paediatric patients with MYCN amplified 
tumours could be treated with lower dosages of the drugs, 
resulting in less toxicity and fewer long lasting sequelae.  
MATERIALS AND METHODS
Plasmid vectors and transfections
The B-Myb responsive plasmid pGL2-mim1, 
containing five MYB binding sites, was constructed as 
follws: two oligonucleotides 5’ CAA CGT TAT AGT GAG 
CTA AGA ACG TTA TAG TGA GCT AAG AAC GTT 
ATA GTG AGC TAA GAA CGT TAT AGT GAG CTA 
AGA ACG TTA TAG TGA GCT AAG C 3’ and 5’ TCG 
AGC TTA GCT CAC TAT AAC GTT CTT AGC TCA 
CTA TAA CGT TCT TAG CTC ACT ATA ACG TTC 
TTA GCT CAC TAT AAC GTT CTT AGC TCA CTA 
TAA CGT TGG TAC 3’ were annealed and subcloned into 
the pGL2-promoter vector (Promega, USA). The pcDNA-
B-MYB plasmid was obtained by subcloning the B-MYB 
cDNA into the pcDNA3.1(+) vector (Invitrogen, UK). 
Transfections were carried out using the Lipofectamine™ 
2000 Reagent (Invitrogen, UK), following the 
manufacturer’s instructions.
Chemical screen and luciferase assays
The Diversity Set II (1364 compounds) and the 
Natural Product Set II (120 compounds) were obtained 
from the National Cancer Institute (NCI, Fisher 
BioServices, Rockville, MD). GIMEN, a MYCN non-
amplified neuroblastoma cell line, was stably transfected 
with the pGL2-mim1 and the pcDna-B-MYB plasmids. 
Stably transfected GIMEN cells were exposed to each 
compound in 96 well plates for 24 h at a final concentration 
of 5 uM. After 24 hours, cells were subjected to luciferase 
assay and compounds causing over 50% inhibition of 
B-Myb transactivation in the absence of overt toxicity 
(i.e. rounding up and detachment of cells from plate) were 
used in validation experiments in which naïve GIMEN 
cells were exposed to the compounds after transient 
transfection of the MYB reporter and B-Myb expressing 
plasmids.  Luciferase assays were performed with the 
Dual-Luciferase Reporter Assay System (Promega, USA), 
following the manufacturer’s instructions, and assessed 
using a luminometer (BERTHOLD TECHNOLOGIES, 
Germany).
Cell Lines
SH-SY5Y, LAN-5 and SK-N-AS cells were 
maintained in culture with DMEM supplemented with 
10% heat-inactivated foetal bovine serum (FBS), 2mM l–
glutamine, penicillin (100mg/ml), streptomycin (100mg/
ml), sodium pyruvate (1mM) and non-essential amino acid 
(NEAA) (0,1mM).
IMR-32, GIMEN and Kelly cells were maintained 
in culture with RPMI 1640 supplemented with 10% heat-
inactivated foetal bovine serum (FBS), 2mM l–glutamine, 
penicillin (100mg/ml), streptomycin (100mg/ml), sodium 
pyruvate (1mM) and non-essential amino acid (NEAA) 
(0,1mM).
SK-N-BE 2 cells were maintained in culture 
with 45% DMEM and 45% Nutrient Mixture F12 Ham 
supplemented with 10% heat-inactivated foetal bovine 
serum (FBS), 2mM l–glutamine, penicillin (100mg/ml), 
streptomycin (100mg/ml), sodium pyruvate (1mM) and 
non-essential amino acid (NEAA) (0,1mM).
SHSY5Y, SK-N-AS, SK-N-BE2, IMR32 and Kelly 
cell lines were purchased from the American Type Culture 
Collection, ATCC. LAN-5 and GIMEN cells were a kind 
gift of Dr. Mirco Ponzoni. 
MTS assay
The CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay is a colorimetric method for 
determining the number of viable cells in proliferation 
or chemosensitivity assays. The CellTiter 96® 
AQueous Assay is composed of solutions of a novel 
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS) and an electron coupling 
reagent (phenazine methosulfate; PMS). MTS is 
bioreduced by cells into a formazan product that is soluble 
in tissue culture medium. The absorbance of the formazan 
at 490nm can be measured directly from 96-well assay 
plates without additional processing. The conversion of 
MTS into aqueous, soluble formazan is accomplished by 
dehydrogenase enzymes found in metabolically active 
cells. The quantity of formazan product as measured by 
the amount of 490nm absorbance is directly proportional 
to the number of living cells in culture.
Cell cycle analysis
Cells were detached with 0.05% Trypsin-EDTA and 
collected by centrifugation at 2000rpm for 10 minutes. 
The cell pellet was resuspended and fixed in 3ml cold Oncotarget 2012; 3:  535-545 543 www.impactjournals.com/oncotarget
70% ethanol for at least 30 minutes. After fixation, the 
cells were centrifuged at 2000rpm for 10 minutes at room 
temperature. The pellet was washed twice in 1ml PBS. 
During each wash, the cells were pelleted at 2,000 rpm 
for 10 minutes at room temperature. To ensure that only 
DNA is stained, cells were treated with 50μl ribonuclease 
A (RNaseA) solution (100μg/ml in PBS). Then 450μl 
of propidium iodide, PI (50μg/ml in PBS), was added 
directly to cells in RNase A solution. Cells were incubated 
for 30 minutes on ice. Samples were analyzed in PI/RNase 
A solution by a BD LSR II flow cytometer. All data for 
flow cytometry were analysed by FlowJo software.
Western blot
Cells were lysates in RIPA Buffer (10 mM Tris-Cl 
(pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% SDS, 140 mM NaCl) and protease/
phosphatase inhibitors (Roche). Proteins were separated 
by SDS/PAGE on 10% gels, transferred to poly vinylidene 
difluoride  membrane  (Amersham  Pharmacia),  and 
incubated with antibodies. Immunoblots were visualized 
by using the enhanced chemiluminescent system 
(Thermo).
Antibodies
Monoclonal anti-B-Myb,[45] was kindly provided 
by Roger Watson. Other primary antibodies used 
were: anti-MycN, anti-Cyclin A, anti-Cyclin B1, anti-
Cdc2, anti-PARP, anti-topoisomerase 1 (Santa Cruz 
Biotechnology) and anti-GAPDH (Cell Signaling). 
Horseradish peroxidase-conjugated secondary antibodies 
were purchased from GE Healthcare Life Sciences. 
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